742 results on '"Eugen-Olsen, Jesper"'
Search Results
2. Early sepsis recognition: how difficult can this be?
3. Development and validation of prognostic machine learning models for short- and long-term mortality among acutely admitted patients based on blood tests
4. qSOFA combined with suPAR for early risk detection and guidance of antibiotic treatment in the emergency department: a randomized controlled trial
5. Intubation Decision Based on Illness Severity and Mortality in COVID-19: An International Study*
6. Social isolation, loneliness, and inflammation: A multi-cohort investigation in early and mid-adulthood
7. Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapy-mediated Viral Suppression.
8. Elevated preoperative suPAR is a strong and independent risk marker for postoperative complications in patients undergoing major noncardiac surgery (SPARSE)
9. Self-rated health and chronic inflammation are related and independently associated with hospitalization and long-term mortality in the general population
10. Chronic inflammation markers and cytokine-specific autoantibodies in Danish blood donors with restless legs syndrome
11. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
12. suPAR cut-offs for stratification of low, medium, and high-risk acute medical patients in the emergency department
13. Prospective and External Validation of Prognostic Machine Learning Models for Short- and Long-Term Mortality Among Acutely Admitted Patients Based on Blood Tests
14. Linking stressful life events and chronic inflammation using suPAR (soluble urokinase plasminogen activator receptor)
15. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
16. Sinus bradycardia is associated with poor outcome in critically ill patients with COVID-19 due to the B.1.1.7 Lineage
17. Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis
18. Soluble urokinase plasminogen activator receptor (suPAR) is lower in disease-free patients but cannot rule out incident disease in patients with suspected cancer
19. Soluble urokinase receptor as a predictor of non-cardiac mortality in patients with percutaneous coronary intervention treated ST-segment elevation myocardial infarction
20. Abnormal routine blood tests as predictors of mortality in acutely admitted patients
21. Social isolation, loneliness, and inflammation: A multi-cohort investigation in early and mid-adulthood
22. Histological and Molecular Adipose Tissue Changes Are Related to Metabolic Syndrome Rather Than Lipodystrophy in Human Immunodeficiency Virus-Infected Patients : A Cross-Sectional Study
23. Capacidad del biomarcador suPAR para estratificar el pronóstico en pacientes atendidos en servicios de urgencias hospitalarios.
24. Overall and inter‐individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes
25. Soluble Urokinase Plasminogen Activator Receptor Is a Predictor of Incident Non-AIDS Comorbidity and All-Cause Mortality in Human Immunodeficiency Virus Type 1 Infection
26. Effect of simvastatin and ezetimibe on suPAR levels and outcomes
27. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments
28. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia
29. Author Correction: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
30. suPAR links a dysregulated immune response to tissue inflammation and sepsis-induced acute kidney injury
31. Plasma Soluble CD163 Level Independently Predicts All-Cause Mortality in HIV-1-Infected Individuals
32. Healthy lifestyles reduce suPAR and mortality in a Danish general population study
33. The biomarkers suPAR and blood eosinophils are associated with hospital readmissions and mortality in asthma – a retrospective cohort study
34. Effects of 1 year of exercise training versus combined exercise training and weight loss on body composition, low-grade inflammation and lipids in overweight patients with coronary artery disease: a randomized trial
35. SuPAR Predicts Cardiovascular Events and Mortality in Patients With Asymptomatic Aortic Stenosis
36. Supplementary Table A2 from Increased Plasma Soluble uPAR Level Is a Risk Marker of Respiratory Cancer in Initially Cancer-Free Individuals
37. Supplementary Figure A1 from Increased Plasma Soluble uPAR Level Is a Risk Marker of Respiratory Cancer in Initially Cancer-Free Individuals
38. Supplementary Table and Figure Legends from Increased Plasma Soluble uPAR Level Is a Risk Marker of Respiratory Cancer in Initially Cancer-Free Individuals
39. Challenges facing the clinical adoption of a new prognostic biomarker: a case study
40. Weight loss is superior to exercise in improving the atherogenic lipid profile in a sedentary, overweight population with stable coronary artery disease: A randomized trial
41. suPAR: A New Biomarker for Cardiovascular Disease?
42. Combining National Early Warning Score With Soluble Urokinase Plasminogen Activator Receptor (suPAR) Improves Risk Prediction in Acute Medical Patients: A Registry-Based Cohort Study
43. Risk assessment models for potential use in the emergency department have lower predictive ability in older patients compared to the middle-aged for short-term mortality – a retrospective cohort study
44. Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population
45. Extracellular Matrix Biomarker, Fibulin-1 and Its Association with Soluble uPAR in a Bi-ethnic South African Population: The SAfrEIC Study
46. Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19
47. Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19
48. Use of the prognostic biomarker suPAR in the emergency department improves risk stratification but has no effect on mortality: a cluster-randomized clinical trial (TRIAGE III)
49. Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD
50. Association of Preoperative Basal Inflammatory State, Measured by Plasma suPAR Levels, with Intraoperative Sublingual Microvascular Perfusion in Patients Undergoing Major Non-Cardiac Surgery
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.